LIFECORE BIOMEDICAL, INC. Other Noncash Income Tax Expense
LIFECORE BIOMEDICAL, INC. (LFCR) reported Other Noncash Income Tax Expense of $5.51 million for the 9-month period ending 2012-02-26, per its 10-Q filed 2012-03-28.
Discontinued › Cash Flow › Operating Activities
us-gaap:OtherNoncashIncomeTaxExpense · last filed 2012-03-28
- LIFECORE BIOMEDICAL, INC. other noncash income tax expense for the quarter ending 2012-02-26 was $2.13M.
- LIFECORE BIOMEDICAL, INC. other noncash income tax expense for the quarter ending 2011-11-27 was $2.10M.
- LIFECORE BIOMEDICAL, INC. other noncash income tax expense for the quarter ending 2011-08-28 was $1.28M, a 59.20% increase year-over-year.
- LIFECORE BIOMEDICAL, INC. other noncash income tax expense for the quarter ending 2010-08-29 was $804.00K.
| Period end | Other Noncash Income Tax Expense 3 month | Other Noncash Income Tax Expense 6 month | Other Noncash Income Tax Expense 9 month |
|---|---|---|---|
| 2012-02-26 | $2.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-03-28 | $4.23M derived: sum of 2 quarters · filed 2012-03-28 | $5.51M 10-Q · filed 2012-03-28 |
| 2011-11-27 | $2.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-01-05 | $3.38M 10-Q · filed 2012-01-05 | |
| 2011-08-28 | $1.28M 10-Q · filed 2011-10-05 | ||
| 2011-02-27 | $2.02M 10-Q · filed 2012-03-28 | ||
| 2010-11-28 | $1.58M 10-Q · filed 2012-01-05 | ||
| 2010-08-29 | $804.00K 10-Q · filed 2011-10-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B |